Dwarfism Medicine Shows Lure of $400,000 Rare-Disease Drugs

David Blaustein waited seven years for the phone call that finally came in December 2010 from BioMarin Pharmaceutical Inc., a maker of medicines for rare diseases.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.